These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Microcirculatory rarefaction in South Asians - a potential mechanism for increased cardiovascular risk and diabetes. Hughes AD; Bathula R; Park C; Tillin T; Wit N; McG Thom S; Chaturvedi N PLoS One; 2013; 8(10):e76680. PubMed ID: 24116136 [TBL] [Abstract][Full Text] [Related]
50. Quantitative assessment of coronary microvascular function in patients with and without epicardial atherosclerosis. Melikian N; Vercauteren S; Fearon WF; Cuisset T; MacCarthy PA; Davidavicius G; Aarnoudse W; Bartunek J; Vanderheyden M; Wyffels E; Wijns W; Heyndrickx GR; Pijls NH; de Bruyne B EuroIntervention; 2010 Apr; 5(8):939-45. PubMed ID: 20542779 [TBL] [Abstract][Full Text] [Related]
51. Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis. Menshikh A; Scarfe L; Delgado R; Finney C; Zhu Y; Yang H; de Caestecker MP Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1383-F1397. PubMed ID: 31509009 [TBL] [Abstract][Full Text] [Related]
52. Microvascular rarefaction and tissue vascular resistance in hypertension. Greene AS; Tonellato PJ; Lui J; Lombard JH; Cowley AW Am J Physiol; 1989 Jan; 256(1 Pt 2):H126-31. PubMed ID: 2912175 [TBL] [Abstract][Full Text] [Related]
53. Renal vascular structure and rarefaction. Chade AR Compr Physiol; 2013 Apr; 3(2):817-31. PubMed ID: 23720331 [TBL] [Abstract][Full Text] [Related]
54. Cell Type Dependent Suppression of Inflammatory Mediators by Myocardin Related Transcription Factors. Liu L; Bankell E; Rippe C; Morén B; Stenkula KG; Nilsson BO; Swärd K Front Physiol; 2021; 12():732564. PubMed ID: 34671275 [TBL] [Abstract][Full Text] [Related]
55. Microvascular rarefaction caused by the NOTCH signaling pathway is a key cause of TKI-apatinib-induced hypertension and cardiac damage. Wang W; Li G; Ma J; Fan X; Lu J; Sun Q; Yao J; He Q Front Pharmacol; 2024; 15():1346905. PubMed ID: 38405666 [TBL] [Abstract][Full Text] [Related]
57. A PHD inhibitor prevents changes in the phosphoproteome and capillary rarefaction by CsA: treatment option for CKD? Schley G; Goppelt-Struebe M Kidney Int; 2022 Oct; 102(4):686-688. PubMed ID: 36150758 [TBL] [Abstract][Full Text] [Related]
58. Myocardial epigenetic modifications link chronic kidney disease to coronary microvascular disease. Sen P; Sorop O; Merkus D Am J Physiol Heart Circ Physiol; 2023 Jan; 324(1):H175-H176. PubMed ID: 36525479 [No Abstract] [Full Text] [Related]
59. Training counteracts DEX-induced microvascular rarefaction by improving the balance between apoptotic and angiogenic proteins. Jesus I; Herrera NA; Andreo JC; Santos CF; Amaral SL Steroids; 2020 Apr; 156():108573. PubMed ID: 31904375 [TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of screening of coronary artery disease in patients with type 2 DIABetes at a very high cardiovascular risk (SCADIAB study) rational and design. Mohammedi K; Préaubert N; Cariou T; Rigalleau V; Foussard N; Piazza L; Bairras-Martin C; Couffinhal T; Bezin J; Benard A Cardiovasc Diabetol; 2021 Mar; 20(1):63. PubMed ID: 33714278 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]